BridgeBio Pharma Net Tangible Assets

BridgeBio Pharma (BBIO) currently reports a net tangible assets of $-2.5B as of June 2026. That compares with $-1.8B in the prior-year period — down 40.9% year over year. Use the charts on this page to explore BridgeBio Pharma's net tangible assets history and peer comparisons.

BridgeBio Pharma's net tangible assets decreased from $-1.8B to $-2.5B — a 40.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BridgeBio Pharma reported $-2.5B in net tangible assets as of June 2026. That compares with $-1.8B in the prior-year period — down 40.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $-2.5B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.

BridgeBio Pharma is classified in the Healthcare sector. On net tangible assets, it currently shows $-2.5B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BBIO with unrelated industries.